Specificity of Dyspnoea Relief With Inhaled Furosemide

Model scores of the 29,894 trials active now.

Model score 3% for any early termination, 1% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 9% of the time (74 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2016-03-31. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Accepts healthy volunteers: Yes (lowers risk) · Who can join
• Wording of the registration (title, summary, criteria) (lowers risk) · Wording Phrases that raised it: acuteworkexpectancylifeattack
  Phrases that lowered it: healthyparticipantsvolunteersdaythe effect
• Design: crossover (lowers risk) · Design
• Sponsor's past termination rate: 0% (lowers risk) · Sponsor's track record
• Phase: 1 (lowers risk) · Design
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Drug's FAERS reports with a death: 17.3% (lowers risk) · Drug's FDA history
• Disease area, cancer: No (lowers risk) · Disease area
• Responsible party: principal investigator (lowers risk) · Design
• Has a data monitoring committee: No (lowers risk) · Design
• Blinding: quadruple (lowers risk) · Design
• Drug's FAERS reports before start: 138470 (lowers risk) · Drug's FDA history
• Minimum age: 18 (raises risk) · Who can join
• Disease area, neurology: No (lowers risk) · Disease area
• Drug's FAERS reports marked serious: 83.1% (lowers risk) · Drug's FDA history
• Drug's FAERS reports in the prior 12 months: 23653 (lowers risk) · Drug's FDA history
• Trials the sponsor started in the prior 2 years: 1 (raises risk) · Sponsor's track record
• Disease area, psychiatry: No (lowers risk) · Disease area
• Sponsor's past trials: 1 (lowers risk) · Sponsor's track record
• Maximum age: not given (raises risk) · Who can join

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Aerosol Inhalation Treatment for Dyspnea NCT01440764 · started 2011 · scored riskier than 12% of active trials completed
• Aerosol Inhalation Treatment for Dyspnea - Patients NCT02524054 · started 2014 · scored riskier than 72% of active trials completed
• Study to Evaluate the Mastery of Inhaler Technique for Budesonide Formoterol (BF) SPIROMAX® as Compared to SYMBICORT® TURBOHALER® as Treatment for Adult Participants With Asthma NCT02062463 · started 2014 · scored riskier than 12% of active trials completed
• Relative Potency of Formoterol Novolizer® 12 µg Compared to Formoterol Aerolizer® 12 µg NCT01256086 · started 2010 · scored riskier than 6% of active trials completed
• To Investigate the Effects of Altering the Time of Day of Dosing (Morning or Evening) With Fluticasone Furoate 100 Micrograms Once Daily Administered Via a Dry Powder Inhaler in Subjects With Asthma NCT01808339 · started 2013 · scored riskier than 4% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.